Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)



Status:Recruiting
Conditions:Gastrointestinal, Hematology
Therapuetic Areas:Gastroenterology, Hematology
Healthy:No
Age Range:Any - 17
Updated:12/16/2018
Start Date:August 31, 2017
End Date:September 2021
Contact:Alexion Pharmaceuticals
Email:clinicaltrials@alexion.com
Phone:1-855-585-8266

Use our guide to learn which trials are right for you!

A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

The purpose of the study is to assess the efficacy of ALXN1210 to control disease activity in
children and adolescents with aHUS who have not previously used a complement inhibitor, as
well as in complement inhibitor experienced adolescent patients.


Inclusion Criteria:

Cohort 1:

1. Patients from birth up to < 18 years of age and weighing ≥ 5 kg at the time of
consent.

2. Evidence of thrombotic microangiopathy (TMA), including low platelet count, hemolysis
(breaking of red blood cells inside of blood vessels), and decreased kidney function.

3. Documented meningococcal vaccination not more than 3 years prior to dosing, and
vaccination against Streptococcus pneumoniae and Haemophilus influenzae

4. Female patients of childbearing potential must use highly effective contraception
starting at screening and continuing until at least 8 months after the last dose of
ALXN1210

Cohort 2:

1. Patients between 12 and <18 years of age who have been treated with eculizumab for
aHUS for at least 90 days prior to Screening

2. Patients with documented diagnosis of aHUS

3. Patients with clinical evidence of response to eculizumab indicated by stable TMA
parameters at Screening

4. Documented meningococcal vaccination not more than 3 years prior to dosing, and
vaccination against Streptococcus pneumoniae and Haemophilus influenzae

5. Females of childbearing potential must use highly effective contraception starting at
screening and continuing until at least 8 months after the last dose of ALXN1210

Exclusion Criteria:

1. ADAMTS13 deficiency (Activity < 5%)

2. Shiga toxin-related hemolytic uremic syndrome (STEC-HUS)

3. Positive direct Coombs test

4. Females who plan to become pregnant during the study or are currently pregnancy or
breastfeeding

5. Identified drug exposure-related hemolytic uremic syndrome (HUS)

6. Bone marrow transplant (BMT)/hematopoietic stem cell transplant (HSCT) within last 6
months prior to start of Screening

7. Known genetic defects of cobalamin C metabolism

8. Systemic sclerosis (scleroderma), systemic lupus erythematosus (SLE), or
antiphospholipid antibody positivity or syndrome

9. Chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy
for end-stage kidney disease (ESKD)

10. For Cohort 2 patients, prior use of complement inhibitors other than eculizumab

11. For Cohort 2 patients, any known abnormal TMA parameters within 90 days prior to
Screening
We found this trial at
7
sites
Aurora, Colorado
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Atlanta, Georgia 30322
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bruxelles,
?
mi
from
Bruxelles,
Click here to add this to my saved trials
1700 Abbey Place
Charlotte, North Carolina 28209
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Detroit, Michigan
?
mi
from
Detroit, MI
Click here to add this to my saved trials
6517 Taft Street
Hollywood, Florida 33021
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
10040 Regency Circle
Omaha, Nebraska 68114
?
mi
from
Omaha, NE
Click here to add this to my saved trials